Dasabuvir
产品说明书
 |
同义名 : | 达塞布韦 ;ABT-333 |
| CAS号 : | 1132935-63-7 | |
| 货号 : | A549431 | |
| 分子式 : | C26H27N3O5S | |
| 纯度 : | 99%+ | |
| 分子量 : | 493.575 | |
| MDL号 : | MFCD27923655 | |
| 存储条件： |
Pure form Sealed in dry, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 45 mg/mL(91.17 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The hepatitis C virus (HCV) is an enveloped, single-strand, positive-sense RNA virus in the Flaviviridae family. The HCV NS5B polymerase has multiple binding sites that can be targeted for inhibition of HCV replication. ABT-333 is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene. It inhibited recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 values between 2.2 and 10.7 nM. In the HCV subgenomic replicon system, dasabuvir inhibited genotype 1a (strain H77) and 1b (strain Con1) replicons with EC50 values of 7.7 and 1.8 nM, respectively. This level of activity was retained against a panel of chimeric subgenomic replicons that contained HCV NS5B genes from 22 genotype 1 clinical isolates from treatment-naive patients, with EC50s ranging between 0.15 and 8.57 nM[3]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02460133 | Hepatitis C Virus | Phase 4 | Active, not recruiting | June 2018 | - |
| NCT03423641 | - | Completed | - | - | |
| NCT02057003 | - | Recruiting | December 2020 | Spain ... 展开 >> Valme University Hospital Recruiting Seville, Spain, 41014 Contact: Karin Neukam, PhD 0034955015799 karin.neukam@gmail.com Contact: Juan A Pineda, MD 0034955015684 japineda@telefonica.net 收起 << | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.03mL 0.41mL 0.20mL |
10.13mL 2.03mL 1.01mL |
20.26mL 4.05mL 2.03mL |
| 参考文献 |
|---|